Examining the potential of Takeda's enzyme replacement therapy, TAK-755 in treating congenital thrombotic thrombocytopenic purpura (cTTP)Ticker(s): TAK
Institution: Case Western
- Professor of Hematology and Oncology in Medicine and Pathology at Case Western Reserve University and University Hospitals Cleveland Medical Center (previously Professor at Temple and Univ. of Michigan)
- Manages 5 patients with cTTP; practice that is exclusively hemostasis, thrombosis, and hemophilia.
- Research has focused on the vascular biology of factor XII and the kallikrein/kinin system and hemostasis and thrombosis.
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.